The benefits that come with using Oncotarget include being able to learn more about treatment, making connections with other specialists and providing people with all of the information that each specialist has been able to learn from his or her own medical practice. There have been many new advances in the medical field thanks to this peer review publication and it has all led back to the fact that Mikhail Blagosklonny wanted to do the best job possible as an oncologist and wanted to make sure that people would be able to get the information that they needed for their own practice. He wanted to create a sense of community in the medical field and also knew that this would be something that he could change when he wanted to help other people out with the options that they had to deal with in the different areas. Oncotarget is also available on Dove Press.
As Mikhail Blagosklonny worked on Oncotarget, he knew that things would change. He also knew that the publication would grow if people liked it and if they were able to get the best experience possible. For Oncotarget to grow in the way that it has is a huge testament to how badly it was needed in the medical community. Mikhail Blagosklonny wanted to make sure that Oncotarget was working in the best way possible and also wanted people to be aware of all of the things that they could be doing for their patients so that they would be able to cure their disease no matter what it was.
One of the things that Mikhail Blagosklonny has taken away from Oncotarget is the ability to study nutrition and how it has an effect on the cell’s rejuvenation. He wants people to be able to learn more about the information that comes along with cell rejuvenation and also wants people to try new things when they have different options in their own field. Since Mikhail Blagosklonny has worked with the people who are in different areas and since he has made sure that things would work in the community, he has found that nutrition is a huge factor in rejuvenation. Visit Oncotarget’s profile page at facebook.com
Eric Lefkofsky is identified as a devoted husband, role model, leader, and most of all – an entrepreneur. Lekofsky is involved with the production of 6 start-up ventures that continue to impact their respective industries. The success of his ventures did not come without its obstacles. His first start-up initiative, Starbelly, had been bought out and eventually went bankrupt trailing major lawsuits. Lefkofsky’s attitude and persistance led to his success in his later ventures.
Today, Mr Lefkofsky and his wife are involved with the Education and Fine Arts community in Chicago. He serves as a Trustee for numerous prominent institutions in Chicago as well as teaches at the University of Chicago.
Tempus is Lefkofsky’s latest start-up venture. Founded in 2016, the technology company was created in response to witnessing how unclear data effected the efficiency and accuracy of results given during his wife’s treatment of breast cancer. The company’s mission is to improve patient outcomes, further stating on their company website that their intention is to “redefine how genomic data is used in a clinical setting.”
Lefkofsky further explains that the amount of data retrieved from cancer studies is not lacking. Instead, he points out that the response and effect that treatments have is not fluid enough for various sources to access. The data of medical history and treatment of a patient is not easily accessed from researchers, clinicians, and others.
Tempus hopes to improve this gap in data through its technology. The technology behind Tempus acts as a layer between existing records and systems, where it takes in data to filter a cleaner version back to each original source for validation and verification. The data behind the layer combining all the patient data can be saved and further studied to find patterns between treatments and results. Click here to know more.
The value of Tempus is timeless. As modern medicine continues to research and discover vaccines, the data utilized will need to be kept in a database to store and build off of for future experiments and discoveries.
Eric Lefkofsky has built an impeccable career in technology. He uses data to create disruptive brands that take over industries such as commerce, manufacturing, media, and healthcare. Mr. Eric is driven by the resolve to helping professionals make calculated decisions through examining scientific research and data. His background in software development, data mining and analytics has put him ahead of other industry players.
In the US alone over 1.7 million new cases of cancer are reported yearly. This number is bound to rise given that factors such as pollution and poor lifestyle habits are not going away anytime soon. It is against this backdrop that Eric Lefkofsky partnered with his longtime friend to build Tempus. The company relies on big data to provide medical solutions to patients. Through the processes of machine learning and analysis of big data, disease, patient and drugs trends can be established. These trends provide information that can be used by doctors so that they can tailor a patient’s medical needs.
In the past few days, Tempus joined hands with the University of Chicago to fight cancer. The University of Chicago is an academic institution of repute while Tempus is a disruptive brand that relies on big data to help professionals make informed decisions. The combination of this two players is bound to spark innovation and advances in the field of oncology. Click here to know more.
Eric Lefkofsky notes that lack of sufficient information in the area of oncology keeps dragging the rate for which effective treatments are designed. With the partnership that Tempus has put in place, the startup is keen on addressing this major problem. Tempus will avail the institution research data of 1,000 patients who have cancer. The University’s medical professionals will then use the data to come up with more personalized therapies for patients. The data to be collected by Tempus shall include, phenotypic and genomic sequences of patients, and the patient’s response to various treatments.
Eric Lefkofsky began his journey in entrepreneurship after graduating from the University of Michigan with a law degree. Together with his business ally, Kenwell they have been the originators of some of the most successful enterprises ranging from the e-commerce giant Groupon to Tempus which is on the list of the most promising startups.